Idorsia
VerifiedThe purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients
Launch date
Employees
Ownership
Market cap
CHF2.4b
Net debt
CHF1.5b
Firm valuation
$3.9b (Public information from 2022)
Share price
CHF13.41 IDIA.SW
Allschwil Canton of Basel-Landschaft (HQ)
Financials
Edit| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E |
|---|---|---|---|---|---|---|---|
| Revenues | - | 132m | 50.8m | 20m | 60m | 29.2m | 109m |
| % growth | - | - | (61 %) | (61 %) | 200 % | (51 %) | 274 % |
| EBITDA | - | 15m | (293m) | (385m) | (326m) | (496m) | (652m) |
| % EBITDA margin | - | 11 % | (577 %) | (1925 %) | (543 %) | (1700 %) | (598 %) |
| Profit | - | (11.7m) | (322m) | (412m) | (371m) | (529m) | (704m) |
| % profit margin | - | (9 %) | (633 %) | (2058 %) | (618 %) | (1814 %) | (645 %) |
| EV / revenue | - | 16.2x | 29.1x | 157.0x | 53.2x | 123.0x | 32.2x |
| EV / EBITDA | - | 142.0x | -5.0x | -8.2x | -9.8x | -7.2x | -5.4x |
| R&D budget | - | 100m | 259m | 367m | 70m | - | - |
| R&D % of revenue | - | 76 % | 510 % | 1835 % | 117 % | - | - |
Source: Company fillings or news article
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - Not yet verified | |
* | N/A | Corporate spinout | |
| N/A | N/A | IPO | |
| N/A | CHF330m | Post IPO Equity Not yet verified | |
| N/A | $632m | Post IPO Equity | |
| Total Funding | - | ||
Recent News about Idorsia
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.